NovoCure registered for an initial public offering that could fetch as much as $300 million for its tumor-zapping Optune brain cancer treatment as it awaits a decision from the FDA on a new indication for the device. The federal safety watchdog granted pre-market approval for Optune in April 2011 for adult patients with glioblastoma whose cancer recurred after […]
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
When Novocure won FDA approval for its Tumor Targeting Field cancer therapy system, the company introduced the oncology world to an entire new modality for treatment.
Cancer patients today are most famliar with surgery, radiation and chemotherapy as thearpy optoins, but certain patients can also opt for Novocure’s non-invasive electromagnetic therapy, which promises to stop cancer cells in their tracks without adding a new suite of side effects.
MASSDEVICE ON CALL — A nationwide urologists lobbying group largely discredited guidance from a U.S. Preventative Services Task Force recommending that physicians set aside a commonly used prostate cancer screening tool.
Known as the prostate-specific antigen test, or PSA, the tool may pose more risks than benefits, according to the panel.
SonoSite (NSDQ:SONO) CFO Marcus Smith stands to pull down more than $3 million now that he’s retired from the Bothell, Wash.-based ultrasound device maker.
The company said Smith’s resignation, which went into effect yesterday, was to pursue other opportunities.
The former Philips Medical Systems exec will end up with more than $3 million in the bank after he receives all of his separation benefits, according to a company filing with the SEC.
Advanced Cell Technology (OTC:ACTC) appointed MIT professor and bioengineering legend Bob Langer to its board of directors, tapping him to lead its science advisory committee.
Langer has authored more than 1,100 journal articles, has more than 800 issued and pending patents and won the 2011 Warren Alpert Foundation Prize for bioengineering pioneers thanks to his work in drug delivery and tissue engineering.
Former OSI Pharmaceuticals Executive joins Novocure’s board of directors and assumes role of Chairman, Global Commercialization Team
PORTSMOUTH, N.H., Oct. 5, 2011 /PRNewswire/ — Novocure, a commercial stage private oncology company, announced today that Gabriel Leung has joined its board of directors. Mr. Leung will serve as vice chairman of the board of directors and chairman of the company’s global commercialization team.
A new treatment for a deadly form of brain cancer has been approved by the FDA and is cleared for sale in the U.S. market.
The NovoTTF-100A System (NovoTTF) made by NovoCure is a “non-invasive device consisting of four sets of insulated electrodes attached to an electronic box,” according to the privately-held Israeli company.
A new treatment for a deadly form of brain cancer has received a favorable vote from an FDA panel, moving the device a step closer to the market.
The FDA’s neurological devices panel voted 7-to-3 with 2 abstains that there is reasonable assurance that the benefits of the NovoTTF-100A System (NovoTTF) made by NovoCure, outweigh its risks when, “administered as a monotherapy in place of standard medical therapy,” according to a prepared release from the company.
A revolutionary treatment for a deadly form of brain cancer failed to show a significant increase in the overall survivability rate when measured against chemotherapy, according to an FDA reviewers document posted on the agency’s web site.
In reviewer materials released ahead of a March 17 meeting of the FDA’s neurological devices panel, Food & Drug Administration officials questioned claims made by NovoCure, a privately-held Israeli company, which is seeking pre-market approval for its NovoTTF-100A device.
A new treatment for a deadly form of brain cancer will get its date before an FDA panel this week, as NovoCure, a privately-held Israeli company, brings its NovoTTF-100A device before the agency’s neurological devices panel March 17.
The NovoTTF is described by the company as a “non-invasive device, consisting of four sets of insulated electrodes attached to an electronic box,” according to product literature on the firm’s website.